New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular dystrophy (DMD). In ...

With recent improvements in healthcare, individuals with Duchenne muscular dystrophy (DMD) have prolonged life expectancy, and it is therefore vital to preserve their independence. Hand function plays ...

The company said it was “surprised” by the decision, which followed the ouster of cell and gene therapy officials from the ...

The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment ...

Duchenne muscular dystrophy – diagnosis, clinical development and global research Its impact on patients, available treatments and why early diagnosis is essential Muscular dystrophy refers to a group ...

Duchenne muscular dystrophy (DMD) is a disease that mainly affects the muscles, but joint issues such as pain and stiffness are also common DMD symptoms. Understanding the causes of joint pain from ...

Scientists present current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec.

The CHMP recommends conditional marketing authorization for Duvyzat to treat Duchenne muscular dystrophy in patients aged 6 years and older who can walk.

Monitoring Duchenne muscular dystrophy helps ensure timely treatment. Learn what doctors watch for as Duchenne MD progresses.

ABSTRACT Duchenne muscular dystrophy (DMD) is a disease characterized by progressive loss of muscle fiber, gradually from proximal to distal. Although a few studies have investigated hand grip ...

SAN DIEGO — Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory boys with Duchenne muscular dystrophy, interim data show.

As innovative treatments emerge for Duchenne muscular dystrophy (DMD), the complexities of caregiver burden are slowly coming into focus, revealing some of the complexities involved in assessing the ...